PTJ
CLSD

Paul Tudor Jones’s Clearside Biomedical CLSD Stock Holding History

Paul Tudor Jones’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,417
Closed -$228K – 1064
2018
Q1 		$228K Buy
+1,417
New +$173K 0.01% 828
2017
Q1 		– Sell
-8,829
Closed -$1.18M – 1390
2016
Q4 		$1.18M Buy
+8,829
New +$2.22M 0.03% 303

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Paul Tudor Jones's CLSD Position: Q2 2018 in Review

Paul Tudor Jones sold out of Clearside Biomedical (CLSD) in Q2 2018, closing a stake of 1,417 shares — an estimated $228K sold.

Paul Tudor Jones first reported a position in CLSD in Q4 2016 and held it in 2 quarters. The position peaked at $1.18M in Q4 2016. 86 funds tracked by Wall St. Rank hold CLSD as of Q2 2018.

  • Paul Tudor Jones reported no remaining Clearside Biomedical position as of Q2 2018 after selling out during the quarter.
  • Paul Tudor Jones sold 1,417 Clearside Biomedical shares in Q2 2018, an estimated $228K.
  • Paul Tudor Jones first reported a position in Clearside Biomedical in Q4 2016 and held it in 2 quarters.
  • Paul Tudor Jones's Clearside Biomedical position peaked at $1.18M in Q4 2016.
  • 86 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2018.

Based on Tudor Investment Corp's 13F filing for Q2 2018, filed 14 Aug 2018.